Gastrointestinal Colorectal Cancer

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes

Treatment for colorectal cancer has advanced over the past several decades and outcomes vary based on tumor-specific molecular features, tumor location, and patient characteristics. It is important to identify the appropriate predictive and prognostic biomarkers for risk stratification of patients with colorectal cancers. This webcast will describe the potential role of circulating tumor DNA (ctDNA) in making therapeutic decisions in colorectal cancer, recent data regarding the nonoperative management of rectal cancer, and first-line systemic regimens for metastatic colon cancer.
 

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Explain the potential benefit of circulating tumor DNA
(ctDNA) in the management of colorectal cancer
2. Discuss treatment plans for patients with rectal cancer who are interested in nonoperative management
3. Identify first-line chemotherapy regimens for metastatic colon cancer based on recent clinical evidence
 

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit
    Horizon CME designates this Enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.50 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 0.50 credit.
Course opens: 
03/15/2023
Course expires: 
03/15/2024
Cost:
$0.00
Rating: 
0

Faculty

Jared Acoba, MD

Dr. Acoba is an Associate Researcher at the University of Hawaiʻi Cancer Center and provides support in both clinical and translational research with a focus on gastrointestinal cancers. His efforts have been in developing (1) clinical trial protocols utilizing novel immunotherapeutic agents for the treatment of gastrointestinal cancers and (2) interventions to reduce racial disparities in cancer treatment.  Dr. Acoba also participates in oncology cooperative groups as a member of the NCI Community Oncology Research Program Minority/Underserved Community Site.

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Jared Acoba, MD has Contracted Research with GSK, during the past 24 months. *

Available Credit

  • 0.50 AMA PRA Category 1 Credit
    Horizon CME designates this Enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.50 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 0.50 credit.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test and score a minimum of 70%
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.v

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above